Surveillance of AMR in DRC
ConditionBacteremia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age6+
SponsorUniversity of Oxford
About this trial
This study addresses knowledge gaps regarding antimicrobial resistance (AMR) in sub-Saharan Africa, focusing on evaluating the feasibility of AMR surveillance and enhancing local research capacity. Conducted at a general referral hospital in semirural Kinshasa, DRC, the study will investigate bacterial infections, their resistance profiles, and related risk factors, including co-infections such as malaria.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
Patients older than 6 months, admitted to the Hospital with a clinical suspicion of bloodstream infection.
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Recruitment process
The feasibility of establishing AMR surveillance at a referral hospital in Kinshasa, DRC will be assessed by evaluating the number of eligible patients, the number of patients who consent and the number of enrolled patients by syndrome each month with blood samples collected.
Time frame
Duration of recruitment, about six months2
Intervention delivery
Another key feasibility metric will be to assess the proportion of samples with final results from the microbiology lab, the proportion of possibly contaminated blood cultures, and the proportion of positive cultures with antimicrobial susceptibility testing.
Time frame
Duration of recruitment, about six months3
Processing time
The time from patient enrolment to blood sample collection and to transfer to the laboratory will be measured.
Time frame
Duration of recruitment, about six months4
Number of Bacterial Bloodstream Infections
The characterization of bacterial bloodstream infections (BSI) will be assessed by the frequency of positive blood cultures in patients with suspected BSI, the proportion of severe falciparum malaria patients diagnosed with concomitant BSI, and the outcome of BSI, in-hospital mortality, and 28-day mortality.
Time frame
Duration of recruitment, about 6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Oxford
Lead sponsor
University of Kinshasa
Collaborator
Mahidol University
Collaborator
Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo
Collaborator
Department of Infectious Diseases, The Alfred Hospital and School of Translational Medicine, Monash University, Melbourne, Australia
Collaborator
Source ClinicalTrials.gov